by Admin | Dec 10, 2018 | Portfolio News
CAMPBELL, Calif., Dec. 10, 2018 /PRNewswire/ — Atia Vision, Inc., a Shifamed portfolio company committed to improving patient outcomes through the development of a modular accommodating intraocular lens, announced today the closing of its second tranche of a...
by Admin | Dec 8, 2018 | Portfolio News
Antios Therapeutics completed a $25 million oversubscribed Series A financing to develop ATI-2173, an oral drug candidate for treating patients with hepatitis B and potentially coinfected with hepatitis D, according to a press release. “The next frontier in virology...
by Admin | Dec 4, 2018 | Portfolio News
December 4, 2018 Early stage medical device developer Tulavi Therapeutics has raised approximately $3 million in a new round of equity financing, according to recently posted SEC filings. Tulavi Therapeutics is developing a medical device-based therapy intended to...
by Admin | Nov 28, 2018 | Portfolio News
Nov. 28, 2018 Tanvex BioPharma, Inc. (TWSE: 6541) announced that US Food and Drug Administration (FDA) has accepted its Biologics License Application for filgrastim (TX-01), which was filed under the new biosimilar pathway created in the Biologics Price Competition...
by Admin | Oct 15, 2018 | Portfolio News
卢凯坚信，“战略合作伙伴平台”的资源整合和保持创新探索的精神，是未来持续发展的关键，这也给了卢凯坚定的信念：“为中国人带来由内而外的健康与美好生活”。如今，卢凯正不断努力履行承诺，进一步感知、洞察中国市场的需求，搭建国际合作伙伴的桥梁，为中国消费者不遗余力地创造更多有价值的产品。...
by Admin | Sep 5, 2018 | Portfolio News
September 05, 2018 Tanvex BioPharma, Inc. (TWSE: 6541) completed its secondary public offering of 25,000,000 shares of common stock on September 04, 2018. The new shares were listed on September 5, 2018. The pricing for this offering was set at NTD 85 per share,...
